317 related articles for article (PubMed ID: 34910154)
1. Comparative Effectiveness of Biologic Agents Among Black and White Medicare Patients in the US With Metastatic Colorectal Cancer.
Goel S; Negassa A; Acuna-Villaorduna A
JAMA Netw Open; 2021 Dec; 4(12):e2136378. PubMed ID: 34910154
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of Biologic Agents Among Hispanic Patients With Metastatic Colorectal Cancer.
Patel R; Negassa A; Tolu SS; Acuna-Villaorduna A; Goel S
Clin Colorectal Cancer; 2024 Mar; 23(1):14-21.e1. PubMed ID: 37919185
[TBL] [Abstract][Full Text] [Related]
3. Comparative Effectiveness Research: The Impact of Biologic Agents in Ethnic Minorities With Metastatic Colorectal Cancer.
Goel S; Negassa A; Khot A; Goyal D; Guo S; Nandikolla A; Bakirhan K; Polineni R; Shah U; Chaudhary I; Ghalib MH; Rajdev L; Kaubisch A; Chuy J; Aparo S
Clin Colorectal Cancer; 2017 Dec; 16(4):286-292. PubMed ID: 28412139
[TBL] [Abstract][Full Text] [Related]
4. Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Mettu NB; Ou FS; Zemla TJ; Halfdanarson TR; Lenz HJ; Breakstone RA; Boland PM; Crysler OV; Wu C; Nixon AB; Bolch E; Niedzwiecki D; Elsing A; Hurwitz HI; Fakih MG; Bekaii-Saab T
JAMA Netw Open; 2022 Feb; 5(2):e2149040. PubMed ID: 35179586
[TBL] [Abstract][Full Text] [Related]
5. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Venook AP; Niedzwiecki D; Lenz HJ; Innocenti F; Fruth B; Meyerhardt JA; Schrag D; Greene C; O'Neil BH; Atkins JN; Berry S; Polite BN; O'Reilly EM; Goldberg RM; Hochster HS; Schilsky RL; Bertagnolli MM; El-Khoueiry AB; Watson P; Benson AB; Mulkerin DL; Mayer RJ; Blanke C
JAMA; 2017 Jun; 317(23):2392-2401. PubMed ID: 28632865
[TBL] [Abstract][Full Text] [Related]
6. Estimates of Overall Survival in Patients With Cancer Receiving Different Treatment Regimens: Emulating Hypothetical Target Trials in the Surveillance, Epidemiology, and End Results (SEER)-Medicare Linked Database.
Petito LC; García-Albéniz X; Logan RW; Howlader N; Mariotto AB; Dahabreh IJ; Hernán MA
JAMA Netw Open; 2020 Mar; 3(3):e200452. PubMed ID: 32134464
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of irinotecan-based chemotherapy regimens in elderly Medicare patients with metastatic colorectal cancer.
Obeidat NA; Pradel FG; Zuckerman IH; DeLisle S; Mullins CD
Am J Geriatr Pharmacother; 2009 Dec; 7(6):343-54. PubMed ID: 20129255
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer.
Sanoff HK; Carpenter WR; Martin CF; Sargent DJ; Meyerhardt JA; Stürmer T; Fine JP; Weeks J; Niland J; Kahn KL; Schymura MJ; Schrag D
J Natl Cancer Inst; 2012 Feb; 104(3):211-27. PubMed ID: 22266473
[TBL] [Abstract][Full Text] [Related]
9. Racial disparities in receipt and comparative effectiveness of oxaliplatin for stage III colon cancer in older adults.
Mack CD; Carpenter W; Meyer AM; Sanoff H; Stürmer T
Cancer; 2012 Jun; 118(11):2925-34. PubMed ID: 22072441
[TBL] [Abstract][Full Text] [Related]
10. Characteristics associated with differences in survival among black and white women with breast cancer.
Silber JH; Rosenbaum PR; Clark AS; Giantonio BJ; Ross RN; Teng Y; Wang M; Niknam BA; Ludwig JM; Wang W; Even-Shoshan O; Fox KR
JAMA; 2013 Jul; 310(4):389-97. PubMed ID: 23917289
[TBL] [Abstract][Full Text] [Related]
11. Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer.
Boisen MK; Johansen JS; Dehlendorff C; Larsen JS; Østerlind K; Hansen J; Nielsen SE; Pfeiffer P; Tarpgaard LS; Holländer NH; Keldsen N; Hansen TF; Jensen BB; Jensen BV
Ann Oncol; 2013 Oct; 24(10):2554-2559. PubMed ID: 23864097
[TBL] [Abstract][Full Text] [Related]
12. Exploring racial differences in outcome and treatment for metastatic colorectal cancer: results from a large prospective observational cohort study (BRiTE).
Polite BN; Sing A; Sargent DJ; Grothey A; Berlin J; Kozloff M; Feng S
Cancer; 2012 Feb; 118(4):1083-90. PubMed ID: 21800287
[TBL] [Abstract][Full Text] [Related]
13. Racial disparity in consultation, treatment, and the impact on survival in metastatic colorectal cancer.
Simpson DR; Martínez ME; Gupta S; Hattangadi-Gluth J; Mell LK; Heestand G; Fanta P; Ramamoorthy S; Le QT; Murphy JD
J Natl Cancer Inst; 2013 Dec; 105(23):1814-20. PubMed ID: 24231453
[TBL] [Abstract][Full Text] [Related]
14. Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer.
Price T; Kim TW; Li J; Cascinu S; Ruff P; Suresh AS; Thomas A; Tjulandin S; Guan X; Peeters M
Eur J Cancer; 2016 Nov; 68():51-59. PubMed ID: 27716478
[TBL] [Abstract][Full Text] [Related]
15. Utilisation of systemic therapy options in routine treatment of metastatic colorectal cancer in Australia.
Delahunty R; Lee M; Wong HL; Johns J; Mckendrick J; Lee B; Kosmider S; Cooray P; Ananda S; Desai J; Tran B; Tie J; Gibbs P; Wong R
Intern Med J; 2020 Feb; 50(2):165-172. PubMed ID: 30887616
[TBL] [Abstract][Full Text] [Related]
16. Assessment of Outcomes Associated With the Use of Newly Approved Oncology Drugs in Medicare Beneficiaries.
Green AK; Curry M; Trivedi N; Bach PB; Mailankody S
JAMA Netw Open; 2021 Feb; 4(2):e210030. PubMed ID: 33625507
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer.
Sherman SK; Lange JJ; Dahdaleh FS; Rajeev R; Gamblin TC; Polite BN; Turaga KK
JAMA Oncol; 2019 Feb; 5(2):236-242. PubMed ID: 30489611
[TBL] [Abstract][Full Text] [Related]
18. Trends in the Incidence of Early-Onset Colorectal Adenocarcinoma Among Black and White US Residents Aged 40 to 49 Years, 2000-2017.
Montminy EM; Zhou M; Maniscalco L; Penrose H; Yen T; Patel SG; Wu XC; Karlitz JJ
JAMA Netw Open; 2021 Nov; 4(11):e2130433. PubMed ID: 34751760
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness of different chemotherapeutic regimens on survival of people aged 66 and older with stage III colon cancer: a "real world" analysis using Surveillance, Epidemiology, and End Results-Medicare data.
Hsiao FY; Mullins CD; Onukwugha E; Pandya N; Hanna N
J Am Geriatr Soc; 2011 Sep; 59(9):1717-23. PubMed ID: 21831168
[TBL] [Abstract][Full Text] [Related]
20. Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.
Bennouna J; Hiret S; Bertaut A; Bouché O; Deplanque G; Borel C; François E; Conroy T; Ghiringhelli F; des Guetz G; Seitz JF; Artru P; Hebbar M; Stanbury T; Denis MG; Adenis A; Borg C
JAMA Oncol; 2019 Jan; 5(1):83-90. PubMed ID: 30422156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
